Multivariate analysis (subset): risks of acute and chronic GVHD, nonrelapse mortality, relapse, and OS by donor type
| . | Transplant conditioning regimen intensity . | |
|---|---|---|
| Outcome . | Myeloablative* . | Reduced intensity† . |
| Hazard ratio (95% CI) . | Hazard ratio (95% CI) . | |
| Grade 2-4 acute GVHD | ||
| Matched unrelated donor | 1.00 | 1.00 |
| Haploidentical donor | 0.37 (0.23-0.61) | 0.71 (0.44-1.15) |
| P = .0001 | P = .16 | |
| Grade 3-4 acute GVHD | ||
| Matched unrelated donor | 1.00 | 1.00 |
| Haploidentical donor | 0.33 (0.14-0.81) | 0.21 (0.05-0.86) |
| P = .02 | P = .03 | |
| Chronic GVHD | ||
| Matched unrelated donor | 1.00 | 1.00 |
| Haploidentical donor | 0.44 (0.29-0.66) | 0.45 (0.28-0.71) |
| P = .0001 | P = .0006 | |
| Nonrelapse mortality | ||
| Matched unrelated donor | 1.00 | 1.00 |
| Haploidentical donor | 0.93 (0.54-1.61) | 0.59 (0.27-1.29) |
| P = .83 | P = .19 | |
| Relapse | ||
| Matched unrelated donor | 1.00 | 1.00 |
| Haploidentical donor | 1.28 (0.911.81) | 1.53 (1.08-2.22) |
| P = .16 | P = .02 | |
| Overall mortality | ||
| Matched unrelated donor | 1.00 | 1.00 |
| Haploidentical donor | 1.19 (0.87-1.61) | 1.06 (0.76-1.51) |
| P = .28 | P = .70 | |
| . | Transplant conditioning regimen intensity . | |
|---|---|---|
| Outcome . | Myeloablative* . | Reduced intensity† . |
| Hazard ratio (95% CI) . | Hazard ratio (95% CI) . | |
| Grade 2-4 acute GVHD | ||
| Matched unrelated donor | 1.00 | 1.00 |
| Haploidentical donor | 0.37 (0.23-0.61) | 0.71 (0.44-1.15) |
| P = .0001 | P = .16 | |
| Grade 3-4 acute GVHD | ||
| Matched unrelated donor | 1.00 | 1.00 |
| Haploidentical donor | 0.33 (0.14-0.81) | 0.21 (0.05-0.86) |
| P = .02 | P = .03 | |
| Chronic GVHD | ||
| Matched unrelated donor | 1.00 | 1.00 |
| Haploidentical donor | 0.44 (0.29-0.66) | 0.45 (0.28-0.71) |
| P = .0001 | P = .0006 | |
| Nonrelapse mortality | ||
| Matched unrelated donor | 1.00 | 1.00 |
| Haploidentical donor | 0.93 (0.54-1.61) | 0.59 (0.27-1.29) |
| P = .83 | P = .19 | |
| Relapse | ||
| Matched unrelated donor | 1.00 | 1.00 |
| Haploidentical donor | 1.28 (0.911.81) | 1.53 (1.08-2.22) |
| P = .16 | P = .02 | |
| Overall mortality | ||
| Matched unrelated donor | 1.00 | 1.00 |
| Haploidentical donor | 1.19 (0.87-1.61) | 1.06 (0.76-1.51) |
| P = .28 | P = .70 | |
BM recipients of haploidentical donor transplants and peripheral blood recipient of matched unrelated donor transplant who received tacrolimus or cyclosporine with methotrexate for GVHD prophylaxis are shown above.
Nonrelapse mortality risk adjusted for performance score; relapse risk adjusted for disease risk index; overall mortality adjusted for patient age and disease risk index.
Nonrelapse mortality risk adjusted for disease risk index; relapse risk adjusted for performance score, disease risk index and secondary AML; overall mortality adjusted for disease risk index and secondary AML.